Lilly Claims 61% of US GLP-1 Market as Novo Bets $23B Pipeline
Lilly holds 61% of the U.S. GLP-1 market and is gaining in pills and Medicare. Novo counters with a $23 billion pipeline bet, but Wall Street wants proof of a turnaround.
Topic
Eli Lilly
Topic
Eli Lilly
Johnson & Johnson Returns 58% on Slower Growth Than Eli Lilly
JNJ returned 58% in twelve months, beating Eli Lilly's 54% despite growing revenue at 8.1% versus Lilly's 49.6%. The rally is a b…
Lilly Claims 70% of 700,000 New Medicare GLP-1 Seniors
Eli Lilly CEO Dave Ricks says 700,000 seniors started GLP-1s since July's Medicare coverage launch — and 70% of them are on Lilly…
Eli Lilly Says One-Third of New GLP-1 Pill Patients Choose Foundayo
One-third of new GLP-1 pill patients pick Foundayo, CEO Dave Ricks says, as Lilly breaks ground on a $6.5 billion Houston plant d…